Derazantinib

Description: Derazantinib / ARQ-087 is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with IC50 values of 1.8 nM for FGFR2, and 4.5 nM for FGFR1 and 3, showing lower potency for FGFR4 (IC50=34 nM). It also inhibits RET, DDR2, PDGFRβ, VEGFR and KIT.

• Catalog: OFC1234356694
• CAS: 1234356-69-4
• Category: Fluorinated APIs
• Synonyms: ARQ-087
• Purity: >98%

• IUPAC Name: (6R)-6-(2-fluorophenyl)-N-[3-[2-(2-methoxyethylamino)ethyl]phenyl]-5,6-dihydrobenzo[h]quinazolin-2-amine
• InChI: InChI=1S/C29H29FN4O/c1-35-16-15-31-14-13-20-7-6-8-22(17-20)33-29-32-19-21-18-26(24-10-4-5-12-27(24)30)23-9-2-3-11-25(23)28(21)34-29/h2-12,17,19,26,31H,13-16,18H2,1H3,(H,32,33,34)/t26-/m1/s1
• InChI Key: KPJDVVCDVBFRMU-AREMUKBSSA-N
• Isomeric SMILES: COCCNCCC1=CC(=CC=C1)NC2=NC=C3C[C@H](C4=CC=CC=C4C3=N2)C5=CC=CC=C5F

• Molecular Formula: C29H29FN4O
• Molecular Weight: 468.58
• Appearance: White to off-white solid powder

• XLogP3-AA: 5.3
• Hydrogen Bond Donor Count: 2
• Hydrogen Bond Acceptor Count: 6
• Rotatable Bond Count: 9
• Exact Mass: 468.23253972 g/mol
• Monoisotopic Mass: 468.23253972 g/mol
• Topological Polar Surface Area: 59.1Ų
• Heavy Atom Count: 35
• Formal Charge: 0
• Complexity: 638